← Issue №14/ week of Oct 4, 2026/Hepatology

Unravelling the Itch: Cross-Sectional Analysis of Pruritus Patterns in the PicnicHealth Primary Biliary Cholangitis Registry.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology retrospective · n=141 · Oct 1, 2026 · Liver International · IF 6.7

Unravelling the Itch: Cross-Sectional Analysis of Pruritus Patterns in the PicnicHealth Primary Biliary Cholangitis Registry.

New evidencePBCbiomarkerepidemiologyhealth services
Clinical takeawayAssess pruritus and its impact on quality of life in all PBC patients, regardless of ALP levels, and consider targeted itch management for those with clinically significant pruritus (PBC-40 itch domain score ≥7).
What it found52% of patients with high ALP (≥1.67 × ULN) reported clinically significant pruritus (PBC-40 itch domain score ≥7), versus 23% with normal ALP (≤1 × ULN).
ContextConfirms pruritus is common in PBC and impacts HRQoL, independent of ALP levels, challenging the assumption that ALP correlates with itch severity.
Measured against the standard of care· AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. If antimitochondrial antibodies (AMA) are negative and PBC is suspected, test for the PBC-specific antinuclear antibodies SP100 and GP210, which may avoid a liver biopsy. Measure liver stiffness (elastography) to estimate the risk of progression; the guideline says the best interval for repeat elastography is unknown. If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. The patient summary names seladelpar and elafibranor, which have FDA accelerated approval as second-line drugs and are not recommended in decompensated cirrhosis. Off-label fibrates (bezafibrate, fenofibrate) are discouraged in decompensated cirrhosis. Obeticholic acid is no longer a US option: it was withdrawn from the market in late 2025, and the 2026 guideline makes no recommendation on it. For moderate-to-severe cholestatic pruritus, consider the IBAT inhibitor linerixibat through shared decision-making that weighs its GI side effects (diarrhea, abdominal pain), cost and patient preference; the older bile-acid sequestrant, rifampin, naltrexone and sertraline ladder from the 2021 guidance still applies. After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. Certainty of evidence ranges from moderate to very low. The guideline found too little evidence to recommend anything for patients who do not respond to second-line therapy, and the long-term effect of PPAR agonists on mortality, transplant-free survival and decompensation is not established.

AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance · reviewed 2026-10-25 ↗
Levy C … Halliday A · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues